TY  - CONF
AU  - Lacerenza, S.
AU  - Moura, D.
AU  - Pena-Chilet, M.
AU  - Hindi, N.
AU  - Dopazo, J.
AU  - Sanchez-Bustos, P.
AU  - Grignani, G.
AU  - Martinez-Trufero, J.
AU  - Redondo, A.
AU  - Valverde, C.
AU  - Stacchiotti, S.
AU  - Lopez-Pousa, A.
AU  - D'Ambrosio, L.
AU  - Perez-Vega, H.
AU  - Collini, P.
AU  - Lopez-Martin, J. A.
AU  - Martin-Broto, J.
PY  - 2021
DO  - 10.1016/j.annonc.2021.08.866
SN  - 0923-7534
UR  - https://hdl.handle.net/10668/27455
T2  - Annals of oncology
AB  - Immunomodulation has emerged as an active therapeutic option in some solid tumors; however, the efficacy of immunotherapy-based regimens is limited in sarcomas or restricted to a few specific subtypes. IMMUNOSARC was a phase Ib/II trial testing the...
LA  - en
PB  - Elsevier
KW  - Humans
KW  - Programmed Cell Death 1 Receptor
KW  - Immunotherapy
KW  - Angiogenesis
KW  - B7-H1 Antigen
KW  - Nivolumab
KW  - Sunitinib
KW  - Sarcoma
KW  - Immunomodulation
TI  - Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups
TY  - conference output
VL  - 32
ER  -